“Translational gaps,” including interspecies differences between animal models and humans, create ample roadblocks during drug discovery. Our roundtable will highlight how innovators are trying to build a better bridge between preclinical and clinical success in neurodegenerative disease therapies by:
- Short-listing the highest-priority issues blocking effective treatments
- Spotlighting promising new strategies for drug discovery and therapeutic development
- Identifying transformations that will enable the drug development process to flow at “the speed of need.”
Insights provided by panelists:
- Rebecca Gilbert, MD, PhD | VP & CSO, American Parkinson Disease Foundation
- Jermaine Ross, PhD | VP & Head of Neuroscience, Immuneering
- Astrid Valles-Sanchez | Director, CNS Disease Biology - uniQure Amsterdam
- Shushant Jain, PhD | Director of Discovery Technology, Ncardia
Our session moderator:
- Andy Holt | Chief Commercial Officer, Ncardia